These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 33296726)

  • 1. Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson's disease.
    Yang J; Luo S; Zhang J; Yu T; Fu Z; Zheng Y; Xu X; Liu C; Fan M; Zhang Z
    Neurobiol Dis; 2021 Jan; 148():105218. PubMed ID: 33296726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomimetic nanodecoys deliver cholesterol-modified heteroduplex oligonucleotide to target dopaminergic neurons for the treatment of Parkinson's disease.
    Huang S; Li YJ; Wu JY; Hao XY; Xu WJ; Tang YC; Zhou M; Zhang JC; Luo S; Xiang DX
    Acta Biomater; 2024 Mar; 177():316-331. PubMed ID: 38244661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of age-associated alpha-synuclein aggregation in a conditional transgenic mouse model of Parkinson's disease: Implications for Lewy body formation.
    Li J; Ng KW; Sung CC; Chung KKK
    J Neurochem; 2024 Jul; 168(7):1215-1236. PubMed ID: 38693066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
    McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
    J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model.
    Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S
    J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Synergistic Effect Study of Lipopolysaccharide (LPS) and A53T-α-Synuclein: Intranasal LPS Exposure on the A53T-α-Synuclein Transgenic Mouse Model of Parkinson's Disease.
    He Q; Zhang S; Wang J; Ma T; Ma D; Wu L; Zhou M; Zhao L; Chen Y; Liu J; Chen W
    Mol Neurobiol; 2024 Sep; 61(9):7046-7065. PubMed ID: 38367134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Induction of Dopaminergic Neuron Loss Accompanied by Lewy Body-Like Inclusions in A53T BAC-SNCA Transgenic Mice.
    Okuda S; Uemura N; Sawamura M; Taguchi T; Ikuno M; Uemura MT; Yamakado H; Takahashi R
    Neurotherapeutics; 2022 Jan; 19(1):289-304. PubMed ID: 34935120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons.
    Luo J; Sun L; Lin X; Liu G; Yu J; Parisiadou L; Xie C; Ding J; Cai H
    Hum Mol Genet; 2014 Dec; 23(24):6567-74. PubMed ID: 25051958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
    Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
    Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GV-971 attenuates α-Synuclein aggregation and related pathology.
    Yu Z; Yang Y; Chan RB; Shi M; Stewart T; Huang Y; Liu Z; Lan G; Sheng L; Tian C; Yang D; Zhang J
    CNS Neurosci Ther; 2024 Feb; 30(2):e14393. PubMed ID: 37563872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
    Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
    Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
    J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.
    Spencer B; Trinh I; Rockenstein E; Mante M; Florio J; Adame A; El-Agnaf OMA; Kim C; Masliah E; Rissman RA
    Neurobiol Dis; 2019 Jul; 127():163-177. PubMed ID: 30849508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
    Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D
    Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.